683
After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).
 children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma: Subject; children: Subject.Age; After completion of induction-consolidation phase: Treatment; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B): Treatment; lymphoblastic lymphoma: Treatment.Disorder; HD MTX: Treatment.Drug; MTX: Treatment.Drug; HD IV Ara-C: Treatment.Drug; MTX: Treatment.Drug; 5 g/m(2): Treatment.Dosage; 1 g/m(2): Treatment.Dosage; over 24 hours every 2 weeks: Treatment.Freq; bolus injection: Treatment.Route; MTX: Combination.Drug; HD IV Ara-C: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma: Subject; children: Subject.Age; After completion of induction-consolidation phase: Treatment; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B): Treatment; lymphoblastic lymphoma: Treatment.Disorder; HD MTX: Treatment.Drug; MTX: Treatment.Drug; HD IV Ara-C: Treatment.Drug; MTX: Treatment.Drug; 5 g/m(2): Treatment.Dosage; 1 g/m(2): Treatment.Dosage; over 24 hours every 2 weeks: Treatment.Freq; bolus injection: Treatment.Route; MTX: Combination.Drug; HD IV Ara-C: Combination.Drug